![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, May 20, 2020 10:06:45 PM
Great insight. I would assume the reason Algernon went with South Korea was the same reason they are going with Australia, that being their affiliation with Novotech. Novotech operates in Southeast Asia and is headquartered in Aussie land. If I remember right, they were already working with Novotech as CRO for IPF prior to Covid19, this is likely the reason they aren't trialing in Japan. The 2B/3 multinational trial for USA/CAN/AUS is set to start July 2020 as per outlined in the clinical trials guidance I posted 2 weeks ago. I would assume AGN is banking on being approved for all 3 before then. Also, we must not forget that Algernon starts a phase 2 trail in AUS late June for chronic cough. This story is literally going to take months to come to fruition, so if anyone is impatient and looking for a quick buck, I'd recommend going elsewhere. But if you have patience and believe in the science of Ifenprodil, you may just get rewarded for your wait. I myself will still be adding on dips as I did today. GL fellow investors.
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM